John L. Wallace was the Founding Director of Farncombe Family Digestive Health Research Institute at McMaster University, and is an Adjunct Professor in the Department of Physiology & Pharmacology at the University of Calgary. He is a pharmacologist with expertise in inflammation research and in the commercialization of new technologies.
Dr. Wallace received his B.Sc. and M.Sc. from Queen’s University and his PhD from the University of Toronto. He completed his post-doctoral studies in the Department of Mediator Pharmacology at Wellcome Research Laboratories in London, England. That work was carried out in a group led by Sir John Vane and Sir Salvador Moncada. Dr. Wallace returned to Canada in 1986 as an Assistant Professor at Queen’s University and in 1989 moved to University of Calgary, where he founded the Inflammation Research Network. In 1996, he co-founded NicOX S.A., based in Nice, France. He served as the Chair of the company’s Scientific Advisory Board from 1996-2003, overseeing the development of nitric oxide-releasing drugs. NicOx went public on the Paris Stock Exchange in 1999, and has an ophthalmic drug in phase 3 clinical trials. In 2004, Dr. Wallace founded Antibe Therapeutics Inc., a company developing hydrogen sulfide-releasing drugs then went on the Toronto Venture Exchange in July of 2013. In 2007, Dr. Wallace completed his MBA degree, with distinction, from the University of Birmingham (UK), which included studies in Mauritius and Singapore, and a dissertation entitled "Evolution of Public Relations Practices in the Pharmaceutical Industry Since 1970.”
He is a Fellow of the Royal Society of Canada, a member of the Brazilian Academy of Science and a Fellow of the British Pharmacological Society. He has won numerous international awards for his research, including the 2009 Premier’s Summit Award ($5 million) and the 2011 William Harvey Medal for Outstanding Contributions to Science, and the 2013 Heyman’s Memorial Award.
Dr. Wallace’s research is focused on mediators of inflammation and their contribution to mucosal injury and dysfunction. He is also interested in the mechanisms of injury induced by the gastrointestinal tract by anti-inflammatory drugs, and the factors that regulate healing of ulcers. Dr. Wallace is attempting to develop GI-sparing anti-inflammatory drugs. He has published approximately 400 peer-reviewed papers 100 book chapters, and is among the top 0.5 per cent of biomedical scientists in the world in terms of citations (Hirsch factor of 93; >28,000 citations). He has delivered over 500 invited lectures around the world.